All Phenotypes Gt(ROSA)26Sor<tm1(cre/ERT)Brn> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}
targeted mutation 1, Anton Berns
MGI:2445311

Summary

13 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} Pou5f1^tm1Jnic/Pou5f1^tm1Jnic	involves: 129P2/OlaHsd	MGI:5610125
cn2	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Trp53bp2^tm2Xlu/Trp53bp2^tm2Xlu	involves: 129P2/OlaHsd	MGI:4819169
cn3	Tbx4^tm1.2Pa/Tbx4^tm1.2Pa Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N	MGI:3811615
cn4	Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J	MGI:5427573
cn5	Nrbp1^tm1.1Dja/Nrbp1^tm1.1Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J	MGI:5427574
cn6	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Lin9^tm1.1Sgau/Lin9^tm1.1Sgau	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL	MGI:4819582
cn7	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Lin9^tm1.1Sgau/Lin9⁺	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL	MGI:4819583
cn8	Atg3^tm1.1Ywh/Atg3^tm1.1Ywh Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6	MGI:5009307
cn9	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Ppp1r13l^tm1Xlu/Ppp1r13l^tm1Xlu	involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J	MGI:5295149
cn10	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6	MGI:3845392
cn11	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6	MGI:3845383
cn12	Fbxo43^tm1.1Kald/Fbxo43^tm1.2Kald Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL	MGI:6201521
cn13	Cdk1^tm3Kald/Cdk1⁺ Fbxo43^tm1.2Kald/Fbxo43^tm1.2Kald Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL	MGI:6201527

Allelic Composition	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} Pou5f1^tm1Jnic/Pou5f1^tm1Jnic
Genetic Background	involves: 129P2/OlaHsd

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Pou5f1^tm1Jnic mutation (0 available); any Pou5f1 mutation (82 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

embryo

abnormal primitive endoderm morphology ( J:208425 )

• embryos isolated at the 8 cell stage then treated with 4-hydroxytamoxifen (4-OHT) for 24 hours then examined 24 hours later show impaired formation of the primitive endoderm

abnormal inner cell mass morphology ( J:208425 )

• impaired lineage segregation of the ICM in 4-OHT treated cultured embryos

• after 5 days in culture 4-OHT treated embryos produce sheets of trophoblast giant cells with no discernible ICM or primitive endoderm derivatives

Allelic Composition	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Trp53bp2^tm2Xlu/Trp53bp2^tm2Xlu
Genetic Background	involves: 129P2/OlaHsd

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Trp53bp2^tm2Xlu mutation (0 available); any Trp53bp2 mutation (53 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

abnormal kidney physiology ( J:162396 )

• in culture primary kidney epithelial cells show a delay in the formation of mature cell junctions

Allelic Composition	Tbx4^tm1.2Pa/Tbx4^tm1.2Pa Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tbx4^tm1.2Pa mutation (1 available); any Tbx4 mutation (23 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:117423 )

• following tamoxifen treatment at E6.5, all mice die at E10.5 due to failure of chorioallantoic fusion

embryonic lethality during organogenesis, incomplete penetrance ( J:117423 )

• following tamoxifen treatment at E7.5, 50% of mice die at E10.5 due to failure of chorioallantoic fusion

limbs/digits/tail

limbs/digits/tail phenotype ( J:117423 )

N	• despite defects in hindlimb formation following treatment with tamoxifen at E9.5 and E10.5, mice exhibit normal hindlimb identity and forelimb development • mice treated with tamoxifen at E11.5 exhibit normal hindlimb morphology

abnormal limb bud morphology ( J:117423 )

• following tamoxifen treatment at E7.5, limb buds form but are degenerating by E11.5 with hindlimb limited outgrowth

abnormal autopod morphology ( J:117423 )

• following tamoxifen treatment at E9.5, the autopod of the hindlimb is thin

• following tamoxifen treatment at E9.5, the space between expression domains of Tbx2 and Tbx3 expression are narrower than in wild type mice and the hindlimb autopod contains fewer cells than in wild-type mice

• however, there is no reduction in cell proliferation rates in the hindlimb autopods of tamoxifen treated mice

abnormal digit morphology ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit abnormal anterior digits of the hindlimb

• following tamoxifen treatment at E10.5, some mice exhibit thin hindlimb digits I and II

fused phalanges ( J:117423 )

• following tamoxifen treatment at E9.5, 33% of mice exhibit fusion of the anterior hindlimb digit; some with parital fusions of digits I and II and others with 4 digits indicating the loss of digit II or fusion of digits I and II

• following tamoxifen treatment at E10.5, 42% of mice exhibit fusion of the anterior hindlimb digits

hindlimb oligodactyly ( J:117423 )

• following tamoxifen treatment at E9.5, 67% of mice exhibit four symmetrical hindlimb digits

• following tamoxifen treatment at E9.5, digits I and II are partially fused in some mice while others have 4 digits indicating the loss of digit II or fusion of digits I and II

absent femur ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit aplastic or severely hypoplastic femurs that do not articulate with the pelvis

short femur ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit aplastic or severely hypoplastic femurs that do not articulate with the pelvis

short fibula ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit hypoplastic fibulas

short hindlimb ( J:117423 )

• following tamoxifen treatment at E9.5 and E10.5, the hindlimb is shorter than in wild type mice at E14.5

abnormal metatarsal bone morphology ( J:117423 )

• following tamoxifen treatment at E10.5, some mice exhibit a metatarsal of the first digit that originates near the middle of the metatarsal of digit two instead of near the tarsal bone

embryo

abnormal limb bud morphology ( J:117423 )

• following tamoxifen treatment at E7.5, limb buds form but are degenerating by E11.5 with hindlimb limited outgrowth

failure of chorioallantoic fusion ( J:117423 )

• following tamoxifen treatment at E6.5, mice die at E10.5 due to failure of chorioallantoic fusion

• following tamoxifen treatment at E7.5, 50% of mice die at E10.5 due to failure of chorioallantoic fusion

skeleton

fused phalanges ( J:117423 )

• following tamoxifen treatment at E10.5, 42% of mice exhibit fusion of the anterior hindlimb digits

absent femur ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit aplastic or severely hypoplastic femurs that do not articulate with the pelvis

short femur ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit aplastic or severely hypoplastic femurs that do not articulate with the pelvis

short fibula ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit hypoplastic fibulas

abnormal metatarsal bone morphology ( J:117423 )

• following tamoxifen treatment at E10.5, some mice exhibit a metatarsal of the first digit that originates near the middle of the metatarsal of digit two instead of near the tarsal bone

abnormal pelvic girdle bone morphology ( J:117423 )

• following tamoxifen treatment at E9.5 or E10.5, mice exhibit abnormal pelvic connections and hypoplastic pelvises

Allelic Composition	Nrbp1^tm1.1Dja/Nrbp1^tm1.2Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Nrbp1^tm1.1Dja mutation (0 available); any Nrbp1 mutation (52 available)
Nrbp1^tm1.2Dja mutation (0 available); any Nrbp1 mutation (52 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

respiratory system

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

mortality/aging

decreased tumor-free survival time ( J:184685 )

• moribund as early as 3 days post tamoxifen treatment

• 75% of mice die 9 days after tamoxifen treatment

• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis

digestive/alimentary system

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

abnormal intestine morphology ( J:184685 )

• loss of architecture in tamoxifen-treated mice with reduction in numbers of differentiated cells, cells showing dysplastic nuclear atypia, widespread crypt elongation, increased crypt fission and reduction in villous length

abnormal intestinal mucosa morphology ( J:184685 )

• in tamoxifen-treated mice

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

distended stomach ( J:184685 )

• in tamoxifen-treated mice

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

neoplasm

increased tumor incidence ( J:184685 )

• tamoxifen-treated mice exhibit increased incidence of tumorigenesis, including lymphomas/leukemias and solid tumors (angiosarcoma, gastrointestinal adenoma, gastrointestinal adenocarcinoma and lung carcinoma)

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

increased leukemia incidence ( J:184685 )

• in tamoxifen-treated mice

increased lymphoma incidence ( J:184685 )

• in tamoxifen-treated mice

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

liver/biliary system

abnormal liver morphology ( J:184685 )

• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice

homeostasis/metabolism

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

Allelic Composition	Nrbp1^tm1.1Dja/Nrbp1^tm1.1Dja Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Nrbp1^tm1.1Dja mutation (0 available); any Nrbp1 mutation (52 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

decreased tumor-free survival time ( J:184685 )

• moribund as early as 3 days post tamoxifen treatment

• 75% of mice die 9 days after tamoxifen treatment

• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis

respiratory system

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

digestive/alimentary system

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

abnormal intestine morphology ( J:184685 )

abnormal intestinal mucosa morphology ( J:184685 )

• in tamoxifen-treated mice

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal intestinal enteroendocrine cell morphology ( J:184685 )

• reduced numbers in tamoxifen-treated mice

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

distended stomach ( J:184685 )

• in tamoxifen-treated mice

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

neoplasm

increased tumor incidence ( J:184685 )

increased gastrointestinal tumor incidence ( J:184685 )

• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma

• 5 of 6 tumors are located in the caecum

increased leukemia incidence ( J:184685 )

• in tamoxifen-treated mice

increased lymphoma incidence ( J:184685 )

• in tamoxifen-treated mice

increased lung carcinoma incidence ( J:184685 )

• in tamoxifen-treated mice

liver/biliary system

abnormal liver morphology ( J:184685 )

• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice

homeostasis/metabolism

intestinal edema ( J:184685 )

• in tamoxifen-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:184685 )

• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice

abnormal enterocyte proliferation ( J:184685 )

• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:184685 )

• elongated in tamoxifen-treated mice

ectopic Paneth cells ( J:184685 )

• altered distribution in tamoxifen-treated mice

Allelic Composition	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Lin9^tm1.1Sgau/Lin9^tm1.1Sgau
Genetic Background	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Lin9^tm1.1Sgau mutation (0 available); any Lin9 mutation (49 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:162678 )

• adult mice die 7 days after tamoxifen treatment

digestive/alimentary system

abnormal small intestinal crypt cell proliferation ( J:162678 )

• tamoxifen-treated mice exhibit reduced cell proliferation with abnormal nuclei and mitotic increased nuclear area compared with wild-type mice

abnormal small intestine morphology ( J:162678 )

• tamoxifen-treated mice exhibit atrophy of the small intestine compared with wild-type mice

abnormal small intestinal villus morphology ( J:162678 )

• 6 days after tamoxifen treatment, mice exhibit a greater than 80% loss of villus epithelium compared with wild-type mice however, no increase in apoptosis is observed

cellular

abnormal centrosome morphology ( J:162678 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit supernumerary centrosomes compared with similarly treated wild-type cells

abnormal cell nucleus morphology ( J:162678 )

• tamoxifen-treated mouse embryonic fibroblasts stimulated with serum exhibit abnormal nuclei including binuclear, multi-lobed, and donut-shaped nuclei compared to similarly treated wild-type cells

abnormal mitosis ( J:162678 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit a delayed entry into mitosis (G2 delay) compared with similarly treated wild-type mice

• tamoxifen-treated mouse embryonic fibroblasts exhibit mitotic errors including chromatin bridges, failed nuclear segregation, cytokinesis failure, chaotic multipolar spindles, and supernumerary centrosomes compared with similarly treated wild-type cells

decreased fibroblast proliferation ( J:162678 )

• following tamoxifen treatment, mouse embryonic fibroblasts exhibit severely impaired proliferation compared with similarly treated wild-type cells

abnormal small intestinal crypt cell proliferation ( J:162678 )

• tamoxifen-treated mice exhibit reduced cell proliferation with abnormal nuclei and mitotic increased nuclear area compared with wild-type mice

Allelic Composition	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Lin9^tm1.1Sgau/Lin9⁺
Genetic Background	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Lin9^tm1.1Sgau mutation (0 available); any Lin9 mutation (49 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal mitotic spindle assembly checkpoint ( J:162678 )

• mouse embryonic fibroblasts treated with tamoxifen and nocodazole exhibit reduced cell cycle arrest compared with similarly treated wild-type mice

Allelic Composition	Atg3^tm1.1Ywh/Atg3^tm1.1Ywh Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atg3^tm1.1Ywh mutation (0 available); any Atg3 mutation (19 available)
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased T cell apoptosis ( J:172749 )

• following tamoxifen stimulation

• however, apoptosis is rescued by IL7 treatment

abnormal T cell morphology ( J:172749 )

• T lymphocytes exhibit increased mitochondria and endoplasmic reticulum content compared with wild-type cells

hematopoietic system

increased T cell apoptosis ( J:172749 )

• following tamoxifen stimulation

• however, apoptosis is rescued by IL7 treatment

abnormal T cell morphology ( J:172749 )

• T lymphocytes exhibit increased mitochondria and endoplasmic reticulum content compared with wild-type cells

cellular

increased T cell apoptosis ( J:172749 )

• following tamoxifen stimulation

• however, apoptosis is rescued by IL7 treatment

Allelic Composition	Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ Ppp1r13l^tm1Xlu/Ppp1r13l^tm1Xlu
Genetic Background	involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ppp1r13l^tm1Xlu mutation (0 available); any Ppp1r13l mutation (39 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal cell cycle ( J:177360 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit a dramatic reduction of S phase entry compared with control mice

abnormal keratinocyte differentiation ( J:177360 )

• tamoxifen-treated primary keratinocyte cultures exhibit increased expression of differentiation markers compared with control cells

decreased fibroblast proliferation ( J:177360 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit decreased proliferation and a 2- to 6-fold increase in slow cycling cells in passage 4 and 5 compared with control mice

early cellular replicative senescence ( J:177360 )

• in tamoxifen-treated mouse embryonic fibroblasts

integument

abnormal keratinocyte differentiation ( J:177360 )

• tamoxifen-treated primary keratinocyte cultures exhibit increased expression of differentiation markers compared with control cells

Allelic Composition	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc25a^tm1.1Hpw mutation (1 available); any Cdc25a mutation (34 available)
Cdc25a^tm1Hpw mutation (1 available); any Cdc25a mutation (34 available)
Cdc25b^tm1Pjd mutation (0 available); any Cdc25b mutation (30 available)
Cdc25c^tm1Hpw mutation (1 available); any Cdc25c mutation (23 available)
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Shortened villi in the small intestine of Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ (TKO) mice

mortality/aging

premature death ( J:145768 )

• adult mice die within 1 week of initial 4-hydroxytamoxifen (OHT) injection

growth/size/body

weight loss ( J:145768 )

• adult mice exhibit significant weight loss (20%) within 1 week of initial tamoxifen injection

digestive/alimentary system

abnormal small intestine crypts of Lieberkuhn morphology ( J:145768 )

• profound cell atrophy in the crypts is observed in OHT-treated mice; crypts are >40% smaller in mutants than Cdc25a-single knockout controls, with the crypt width being decreased more significantly than the depth

• a 70% loss of epithelial cells per crypt is detected, but no difference in mature Paneth cells is observed

• decreased proliferation of epithelial cells is observed, with no significant increase in apoptotic cell numbers; this results in premature differentiation of cell progenitors below Paneth cell compartments in crypts

• crypts have increased numbers of cells exhibiting early differentiation with no crypt base columnar (CBC) cells

abnormal small intestinal villus morphology ( J:145768 )

• villi are lined with shorter, less-dense enterocytes in proximal regions; complete loss of distal villi is observed in some areas

decreased small intestinal villus height ( J:145768 )

• significant loss of villus height in proximal and distal regions is observed in mutants after OHT treatment

decreased small intestine length ( J:145768 )

• 6 days following the final of 3 consecutive injections of tamoxifen, length of small intestine is shortened by 40% compared to controls

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:145768 )

• a 70% loss of epithelial cells per crypt is detected, but no difference in mature Paneth cells is observed

• crypts have increased numbers of cells exhibiting early differentiation with no crypt base columnar (CBC) cells

Allelic Composition	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

digestive/alimentary system

digestive/alimentary phenotype ( J:145768 )

N	• no difference in villi height is after 4-hydroxytamoxifen treatment observed after in contrast to triple knockout mice

Allelic Composition	Fbxo43^tm1.1Kald/Fbxo43^tm1.2Kald Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fbxo43^tm1.1Kald mutation (0 available); any Fbxo43 mutation (29 available)
Fbxo43^tm1.2Kald mutation (0 available); any Fbxo43 mutation (29 available)
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

increased male germ cell apoptosis ( J:251984 )

• at stage XII (pachytene/diplotene) in tamoxifen-treated mice

male infertility ( J:251984 )

• in tamoxifen-treated mice

cellular

increased male germ cell apoptosis ( J:251984 )

• at stage XII (pachytene/diplotene) in tamoxifen-treated mice

Allelic Composition	Cdk1^tm3Kald/Cdk1⁺ Fbxo43^tm1.2Kald/Fbxo43^tm1.2Kald Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk1^tm3Kald mutation (0 available); any Cdk1 mutation (21 available)
Fbxo43^tm1.2Kald mutation (0 available); any Fbxo43 mutation (29 available)
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:251984 )

• within 4 to 5 days after treatment with tamoxifen at around age P21

reproductive system

azoospermia ( J:251984 )

• after treatment with tamoxifen at around age P21

arrest of male meiosis ( J:251984 )

• early in diplotene with some progression into metaphase

increased male germ cell apoptosis ( J:251984 )

• after treatment with tamoxifen at around age P21

cellular

azoospermia ( J:251984 )

• after treatment with tamoxifen at around age P21

arrest of male meiosis ( J:251984 )

• early in diplotene with some progression into metaphase

increased male germ cell apoptosis ( J:251984 )

• after treatment with tamoxifen at around age P21

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24